Open Orphan PLC Upcoming Investor Events
02 Setembro 2019 - 3:00AM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
02 September 2019
02 September 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Upcoming Investor Events
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce that the
Company will be attending and presenting at a series of investor
events from the 4(th) September to 10(th) October 2019.
Cathal Friel, Open Orphan's Chief Executive Officer, will be in
attendance for all of the events and will be presenting to update
existing and potential investors on the Company's business plans
for 2019-2020.
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
Event Date/Time Location
Shares Magazine September 4(th) London - Novotel Tower Bridge, EC3N
Investor Evening 2019 2NR
18:00 - 21:30
ShareSoc Growth September 11(th) London - 65 Gresham Street, London,
Company Seminar 2019 EC2V 7NQ
17:30
------------------ --------------------------------------
London South September 11(th) London - Brewers Hall, Aldermanbury
East Biotech 2019 Square, London EC2V 7HR
Investor Evening
18:30
------------------ --------------------------------------
Shares Magazine September 12(th) Edinburgh - Radisson Blu Hotel,
Investor Evening 2019 EH1 1TH
17:20 - 21:30
------------------ --------------------------------------
Total Market September 18(th) London, Moorgate
Solutions 2019 12:30-15:00
------------------ --------------------------------------
Proactive Investors September 18(th) London - Chesterfield Mayfair Hotel,
One2One Forum 2019 35 Charles Street, Mayfair, W1J
5EB in the Charles Suite (1st Floor)
18:00 - 20:00
------------------ --------------------------------------
Shares Magazine October 10(th) Manchester - Macdonald Manchester
Investor Evening 2019 18:00 Hotel, M1 2PG
------------------ --------------------------------------
Enquiries:
Open Orphan Plc Tel: +353 1 5499 341
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug
consulting services platform. The Company consists of four
elements: a European clinical research organisation and
consultancy; an orphan drug services business; a Virtual Rep and
Data Access Platform consisting of physicians and key opinion
leaders; and a Health Data Platform to partner with Patient
Advocacy Groups. The Company is targeting rapid growth in one of
the fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAKPEDAPNEFF
(END) Dow Jones Newswires
September 02, 2019 02:00 ET (06:00 GMT)
Venn Life Sciences (LSE:VENN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Venn Life Sciences (LSE:VENN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
